Isatuximab approved for use in EU for multiple myeloma

The decision follows data showing that isatuximab in combination with pomalidomide and dexamethasone significantly cut the risk of progression or death by 40% versus pomalidomide and dexamethasone alone.

Source:

PharmaTimes